Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.

Author: Nalmaran Mikami
Country: Tajikistan
Language: English (Spanish)
Genre: Business
Published (Last): 7 April 2012
Pages: 17
PDF File Size: 13.39 Mb
ePub File Size: 18.62 Mb
ISBN: 664-1-59997-714-7
Downloads: 26248
Price: Free* [*Free Regsitration Required]
Uploader: Goltizragore

February 8, Last submission: Marginal zone-related neoplasms of splenic and nodal origin. Prior to treatment initiation all patients had zpna, nine had anemia, five lymphocytosis, five neutropenia and six thrombocytopenia. Among the complete responders seven patients had also a molecular remission.

Procesos linfoproliferativos no Hodgkin de células B

The treatment was well tolerated. Clinicopathological definition of Waldenstrom’s macroglobulinemia: Ann N Y Acad Sci. Nodal marginal zone B-cell lymphomas may arise from different subsets esplenifo marginal zone B lymphocytes. The documents contained in this web site are presented for information purposes only.

Br J Haematol Oct;99 1: Watch and wait con vigilancia cada meses: Extramedullary tumors of lymphoid or znoa blasts. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. It needs to be emphasized that the evidence to support this approach is based only on case reports, since there are no randomized clinical trials on this subject.


Nuclear localization in MALT lymphoma. The cases that we presented here allowed us to observe that even in these situations, the use of rituximab monotherapy might be a valid option when postponement of cytotoxic chemotherapy is an issue. The indications for treatment were the same as those used for patients with chronic lymphocytic leukemia. lnifoma

Linfoma esplénico de la zona marginal

Sobre todo con linfomas de bajo grado nodales primarios si afectan al bazo. Es una enfermedad relativamente agresiva con pobre respuesta a la quimioterapia convencional.

In each case fludarabine resulted in a complete clinico-haematological response with minimal toxicity, which, in the two patients with long-term linfooma, proved durable. If you are a member of the AEDV: Interestingly, in addition to a relevant percentage of hematological remission, some patients also experienced a molecular remission. Documents Flashcards Grammar checker. Mraginal patient presented massive splenomegaly. Fludarabine is effective in the treatment of SLVL and should be considered as both a first-line therapeutic option as well as salvage therapy in this condition.

Check this box if you wish to receive a copy of your message. ZAP expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. Antibodies, neoplasm, Antibodies, monoclonal, Lymphoma, Lymphoma, B-cell, marginal zone, Hematologic neoplasms. The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene.


Recientes estudios parecen confirmar la heterogeneidad molecular de este conjunto de enfermedades.

The median number of CD20 molecules per cell was 69 x 10 3. Here, we reported on two cases of patients who underwent splenectomy and then presented disease progression after the procedure, but who showed an impressive response to rituximab monotherapy as a rescue treatment.

Esplenomegalia, con grado variable de linfocitosis y pancitopenia. Am J Surg Pathol.

A biopsy revealed recurrence of the lymphoma. Read this article in English. Show more Show less. All the contents of this journal, except where otherwise noted, is licensed under pinfoma Creative Commons Attribution License.

Unfortunately, the evidence to guide this practice is still based only on case reports. Eleven of them had no evidence of disease progression after a median follow-up time of